Table 3.
Univariate outcome of patients ≥ 18 year receiving allogeneic transplants for CML in first chronic phase, reported to the CIBMTR, 1990–2004.
| HLA-matched Siblings Donor |
Unrelated Donor |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Smoker Groupa | Never | Low Dose | High Dose | Never | Low dose | High Dose | ||||||||
| Outcomes | N | (95% CI) | N | (95% CI) | N | (95% CI) | P-value | N | (95% CI) | N | (95% CI) | N | (95% CI) | P-value |
| Relapse | 1565 | 347 | 88 | 514 | 119 | 30 | 0.837 | |||||||
| 100 days | 1 (0–1) | 1 (0–3) | 0 | 0.013 | 1 (0–2) | 1 (0–3) | 0 | |||||||
| 1 year | 3 (2–4) | 6 (4–9) | 3 (1–8) | 3 (2–5) | 3 (1–8) | 0 | ||||||||
| 3 years | 6 (5–8) | 9 (6–12) | 3 (1–8) | 6 (4–8) | 5 (2–10) | 0 | ||||||||
| 5 years | 8 (7–9) | 10 (7–14) | 6 (2–12) | 7 (5–9) | 5 (2–10) | 0b | ||||||||
| TRM | 1565 | 347 | 88 | <0.001 | 514 | 119 | 30 | 0.200 | ||||||
| 100 days | 12 (10–13) | 11 (8–15) | 17 (10–26) | 23 (19–26) | 19 (13–27) | 33 (18–51) | ||||||||
| 1 year | 22 (20–25) | 24 (20–29) | 28 (20–38) | 41 (37–46) | 42 (33–51) | 57 (39–74) | ||||||||
| 3 years | 27 (24–29) | 29 (24–34) | 41 (31–52) | 46 (42–51) | 48 (39–57) | 64 (46–80) | ||||||||
| 5 years | 28 (25–30) | 32 (27–37) | 50 (40–61) | 49 (44–53) | 50 (41–59) | 68 (50–83) | ||||||||
| DFS | 1565 | 347 | 88 | <0.001 | 514 | 119 | 30 | 0.293 | ||||||
| 100 days | 88 (86–89) | 87 (83–90) | 83 (74–90) | 76 (72–80) | 80 (72–86) | 67 (49–82) | ||||||||
| 1 year | 75 (73–77) | 70 (65–75) | 68 (58–77) | 56 (51–60) | 54 (45–63) | 43 (26–61) | ||||||||
| 3 years | 67 (65–69) | 63 (57–68) | 55 (45–66) | 48 (43–52) | 47 (37–56) | 36 (20–54) | ||||||||
| 5 years | 64 (62–67) | 58 (52–63) | 44 (33–54) | 44 (40–49) | 44 (35–54) | 32 (17–50) | ||||||||
| Bronchopneumonia | 1575 | 363 | 88 | 0.602 | 512 | 129 | 30 | 0.963 | ||||||
| 100 days | 10 (8–11) | 12 (9–16) | 11 (6–19) | 16 (13–19) | 15 (9–21) | 10 (2–23) | ||||||||
| 1 year | 18 (16–20) | 17 (14–21) | 19 (11–28) | 25 (21–29) | 26 (18–34) | 23 (10–40) | ||||||||
| 3 years | 23 (21–25) | 23 (19–28) | 26 (17–36) | 30 (26–35) | 29 (21–37) | 31 (16–48) | ||||||||
| 5 years | 25 (22–27) | 26 (21–31) | 26 (17–36) | 30 (26–35) | 31 (23–40) | 31 (16–48) | ||||||||
| IPN | 1634 | 359 | 94 | 0.018 | 534 | 129 | 29 | 0.671 | ||||||
| 100 days | 6 (5–7) | 8 (5–11) | 14 (8–22) | 13 (10–16) | 12 (7–19) | 14 (4–28) | ||||||||
| 1 year | 11 (10–13) | 12 (9–15) | 21 (13–30) | 20 (16–23) | 17 (11–25) | 21 (8–37) | ||||||||
| 3 years | 12 (11–14) | 14 (10–18) | 21 (13–30) | 21 (17–24) | 18 (12–26) | 25 (11–42) | ||||||||
| 5 years | 13 (11–15) | 15 (11–19) | 21 (13–30) | 21 (18–25) | 18 (12–26) | 25 (11–42) | ||||||||
| BO | 1320 | 298 | 78 | 0.731 | 444 | 104 | 25 | 0.473 | ||||||
| 100 days | 0 (0–1) | 0 | 1 (0–5) | 0 (0–1) | 0 (0–100) | 0 (0–100) | ||||||||
| 1 year | 2 (1–3) | 3 (1–5) | 3 (0–7) | 3 (2–5) | 2 (0–6) | 0 (0–100) | ||||||||
| 3 years | 4 (3–5) | 4 (2–7) | 4 (1–10) | 5 (3–7) | 2 (0–6) | 8 (0–27) | ||||||||
| 5 years | 4 (3–6) | 5 (2–8) | 6 (2–13) | 5 (3–8) | 2 (0–6) | 8 (0–27) | ||||||||
| Overall survival | 1649 | 370 | 88 | <0.001 | 512 | 119 | 30 | 0.278 | ||||||
| 100 days | 88 (86–89) | 88 (84–91) | 83 (74–90) | 76 (72–79) | 80 (71–86) | 67 (49–82) | ||||||||
| 1 year | 76 (74–78) | 73 (69–78) | 72 (62–80) | 56 (52–60) | 56 (47–65) | 43 (26–61) | ||||||||
| 3 years | 70 (68–73) | 66 (62–71) | 59 (48–69) | 50 (46–54) | 48 (39–57) | 36 (20–54) | ||||||||
| 5 years | 68 (66–70) | 62 (57–67) | 50 (40–61) | 46 (41–50) | 46 (37–55) | 32 (17–50) | ||||||||
Low dose smokers=smoking ≤ 10 pack-years or > 10 pack-years with 1 ≤ pack/day; high dose smokers=smoking ≥ 10 pack-years with > 1 pack/day.
No relapses were reported for the high dose smokers in the unrelated donor group, though small sample size and high TRM are important considerations. Confidence intervals are not relevant.
Abbreviations: TRM=Treatment related mortality, DFS=Disease free survival, IPN= interstitial pneumonitis, BO=Broncholitis obliterans, CI=Confidence interval.
Note: Comparing Non-smoker and low dose smoker vs. high dose smoker in the unrelated donor group:
Relapse: P-value=0.685
TRM: P-value=0.074
Overall survival: P-value=0.115